Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Esophageal Achalasia01:27

Esophageal Achalasia

22
Esophageal achalasia is a chronic neurogenic disorder characterized by impaired relaxation of the lower esophageal sphincter (LES) and absent or ineffective peristalsis in the distal esophagus. This leads to a functional obstruction without a physical blockage, despite significant disruption of esophageal motility.EtiologyAchalasia is caused by degeneration of the myenteric (Auerbach's) plexus, specifically the loss of inhibitory ganglion cells that produce vasoactive intestinal peptide...
22
Esophageal Strictures-I: Introduction01:30

Esophageal Strictures-I: Introduction

1.3K
Esophageal strictures involve abnormal narrowing or tightening of the esophagus. They vary in length and severity, ranging from mild constriction to complete obstruction, and are classified as benign (noncancerous) or malignant (cancerous).
Etiology
The primary cause of esophageal strictures is long-standing gastroesophageal reflux disease (GERD), accounting for about 70 to 80% of adult cases. Chronic acid reflux can lead to injury and scarring of the esophageal lining, culminating in...
1.3K
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

21
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
21
Endocarditis II: Clinical Features of Infective Endocarditis01:25

Endocarditis II: Clinical Features of Infective Endocarditis

907
Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
907
Other Disorders of Digestive System01:30

Other Disorders of Digestive System

1.8K
The gastrointestinal tract is susceptible to various disorders. If the lower esophageal sphincter is damaged, stomach acid can flow back into the esophagus, causing irritation and inflammation of the lining. This condition is called gastroesophageal reflux disease (known as heartburn) and may cause chest pain and difficulty swallowing. In the stomach, prolonged use of nonsteroidal anti-inflammatory drugs like aspirin, chronic alcohol consumption, bacterial infections such as Helicobacter...
1.8K
Cholecystitis01:20

Cholecystitis

20
Cholecystitis is inflammation of the gallbladder, most commonly caused by obstruction of the cystic duct. This blockage prevents bile from draining, leading to gallbladder distension, inflammation, and potentially serious complications. This condition may present acutely or chronically and can happen with or without gallstones.EtiologyAbout 95% of cholecystitis cases are calculous, caused by gallstones blocking the cystic duct, leading to bile accumulation and inflammation of the gallbladder...
20

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Water chemistry controlled enhancement of electrokinetic transport and reactant delivery in low-permeability zones.

Water research·2026
Same author

Toward Decarbonized Metal Mining and Shifting Environmental Impacts: A Quantitative Comparative Assessment.

Environmental science & technology·2026
Same author

Giant Maxillary Antral Mucocele Consequent To Allergic Fungal Sinusitis.

Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India·2025
Same author

The crucial balance in surgical margins for head and neck oncology.

Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale·2025
Same author

The crucial balance in surgical margins for head and neck oncology.

Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale·2025
Same author

Prognostic significance of surgical margins in laryngeal cancer treated by transoral laser microsurgery: a systematic review and meta-analysis.

Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale·2025

Related Experiment Video

Updated: Apr 19, 2026

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

966

Churg-Strauss syndrome.

Antonio Greco1, Maria Ida Rizzo2, Armando De Virgilio3

  • 1Department Organs of Sense, ENT Section, University of Rome "La Sapienza", Viale del Policlinico 155, 00100 Roma, Italy.

Autoimmunity Reviews
|December 16, 2014
PubMed
Summary

Churg-Strauss syndrome (CSS), or EGPA, is a rare vasculitis linked to asthma and eosinophilia. Treatment for EGPA involves corticosteroids, cyclophosphamide, or newer biological agents based on prognosis.

Keywords:
ANCA-associated vasculitisAsthmaChurg–Strauss syndromeEosinophilic granulomatosis with polyangiitisHypereosinophilic syndromesWegener granulomatosis

More Related Videos

Forward Genetic Approaches in Chlamydia trachomatis
09:03

Forward Genetic Approaches in Chlamydia trachomatis

Published on: October 23, 2013

13.4K
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

21.2K

Related Experiment Videos

Last Updated: Apr 19, 2026

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

966
Forward Genetic Approaches in Chlamydia trachomatis
09:03

Forward Genetic Approaches in Chlamydia trachomatis

Published on: October 23, 2013

13.4K
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

21.2K

Area of Science:

  • Rheumatology
  • Immunology
  • Pathology

Background:

  • Churg-Strauss syndrome (CSS), now eosinophilic granulomatosis with polyangiitis (EGPA), is a rare necrotizing vasculitis associated with asthma and eosinophilia.
  • EGPA is a small-vessel vasculitis linked to antineutrophil cytoplasmic antibodies (ANCAs) and hypereosinophilic syndromes, where inflammation and eosinophilic proliferation cause organ damage.
  • Traditionally viewed as Th2-mediated, recent evidence suggests ANCAs, B cells, and humoral responses play direct roles in EGPA pathogenesis.

Purpose of the Study:

  • To review the pathogenesis, classification, and treatment of EGPA.
  • To highlight the evolving understanding of EGPA's underlying mechanisms.
  • To discuss current and emerging therapeutic strategies for EGPA.

Main Methods:

  • Literature review of EGPA pathogenesis, classification criteria, and treatment modalities.
  • Analysis of traditional and emerging evidence regarding immune system involvement in EGPA.
  • Examination of prognostic factors and treatment outcomes in EGPA patients.

Main Results:

  • EGPA typically progresses through prodromal, eosinophilic, and vasculitic phases.
  • Classification relies on American College of Rheumatology criteria, while prognosis is assessed using the French Vasculitis Study Group's five-factor score (FFS).
  • High-dose corticosteroids and cyclophosphamide remain standard for severe EGPA, with rituximab and mepolizumab showing promise as alternatives.

Conclusions:

  • EGPA is a complex vasculitis with multifactorial pathogenesis.
  • Accurate classification and prognostic assessment are crucial for tailoring EGPA treatment.
  • Biologics represent a promising advancement in managing EGPA, offering alternatives to traditional therapies.